FY2027 EPS Estimate for Bausch Health Cos Reduced by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Analysts at Zacks Research reduced their FY2027 EPS estimates for Bausch Health Cos in a research note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $3.85 for the year, down from their previous forecast of $4.34. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share.

A number of other research analysts also recently issued reports on BHC. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

Bausch Health Cos Stock Performance

BHC stock opened at $6.04 on Friday. The stock’s 50 day simple moving average is $6.45 and its 200 day simple moving average is $6.26. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $8.69. The stock has a market capitalization of $2.24 billion, a PE ratio of 23.23 and a beta of 0.47.

Institutional Investors Weigh In On Bausch Health Cos

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Private Management Group Inc. boosted its holdings in shares of Bausch Health Cos by 13.8% in the first quarter. Private Management Group Inc. now owns 1,439,426 shares of the company’s stock worth $9,313,000 after buying an additional 174,176 shares during the last quarter. Federated Hermes Inc. purchased a new stake in Bausch Health Cos during the first quarter valued at approximately $758,000. XTX Topco Ltd bought a new position in Bausch Health Cos in the first quarter worth approximately $139,000. Wealthquest Corp purchased a new position in shares of Bausch Health Cos during the 1st quarter worth $58,000. Finally, Cary Street Partners Financial LLC bought a new stake in shares of Bausch Health Cos during the 1st quarter valued at $27,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.